Houston-based BrainCheck has expanded into its own office space, innovators to know, and The Ion names new leadership — here are this week's top stories. Photo courtesy of BrainCheck

Editor's note: This week's top stories include new office space for a growing Houston health tech company, an energy software-as-a-service startup raises more money than it expected, and more trending innovation news.

3 Houston innovators to know this week

This week's innovators to know are focused on bringing startup programming and venture capital to Houston. Courtesy photos

This past week has been full of exciting innovation news in Houston — from big fundraising round closings to a new unicorn coming out of the Bayou City.

Houston innovators to know this week include a new program director for Houston's newest startup accelerator, a venture capital fund leader, and more. Continue reading.

Houston health tech startup moves into new office amid major growth

BrainCheck has moved to a new office as it grows its team and expands its product. Natalie Harms/InnovationMap

Following a series A round of fundraising, a Houston digital health startup is on a bit of a hiring spree, leading to new office space the company has room to grow into.

BrainCheck, which was founded in 2015 by neuroscientist David Eagleman, is a cognitive assessment startup that has developed a software tool for primary care doctors to use to assess their patients' cognitive health so that they can more quickly diagnose and treat them for maladies like dementia.

The 19-person company headquartered in Houston — with a secondary office in Austin focused on product development — has relocated its operations from coworking space in the Texas Medical Center to an office in the Rice Village area. The move was made possible by an $8 million series A financing round that closed in October. Continue reading.

TMCx company receives investment from Houston VC, UH program recognized, and more innovation news

TMCx

A TMCx company has raised money in Houston, UH's online program named best in the nation, and more Houston innovation news. Courtesy of TMCx

Houston's innovation ecosystem has seen a busy January so far — the city has claimed a unicorn in High Radius, The Ion has named a series of new execs, and so much more.

Given this influx of news, you might've missed some other Houston innovation headlines, like UH being recognized for its online master's program, recent fundings, and Texas being named a state for female entrepreneurs. Here's a few short stories to catch you up. Continue reading.

The Ion Houston names 3 new execs to its team

Jan E. Odegard, Deanea LeFlore, and Chris Valka have been named senior directors at The Ion. Photos courtesy of The Ion

The Ion, an entrepreneurship center being developed in the old Sears building in Midtown by the Rice Management Company, has named three new senior directors to its team.

Deanea LeFlore, Jan E. Odegard, and Chris Valka are the three newly named leaders of the organization, effective immediately. They join — and will report to — Gabriella Rowe, who was named executive director in October.

"To grow the Houston innovation system and spearhead our mission for the Ion we've hired three new leaders with fresh perspectives, ideas, and approaches," says Allison K. Thacker, president and chief investment officer of the Rice Management Company, in a news release. "Each individual has a unique connection to Houston and the Ion, and we're thrilled to have them join our effort to build on the culture of innovation across our city, and within the community we're cultivating at the Ion." Continue reading.

Houston-based oil and gas software company raises $1.6 million

XXXL pumpjack silhouettes

Houston-based M1neral has raised $1.6 million in an oversubscribed pre-seed round. Getty Images

A Houston energy tech startup that's digitally optimizing the minerals rights buying and selling process has closed an oversubscribed pre-seed financing round to the tune of $1.6 million.

M1neral's round was co-led by Amnis Ventures and Pheasant Energy, among a few other select investors and strategic partners. The company was co-founded by Jacob Avery, Kyle Chapman, and Shawn Cutter.

"Amnis Ventures is delighted to co-lead the current round of funding in M1neral. The founders come with deep knowledge of oil and gas, coupled with proven, delivered technology implementations in the energy space," says Manuel Silva III, president of Amnis Ventures Inc., in a press release. "The M1neral platform will bring age-old upstream oil and gas processes into the technology revolution of the 21st century that we have come to expect in other sectors." Continue reading.

Jan E. Odegard, Deanea LeFlore, and Chris Valka have been named senior directors at The Ion. Photos courtesy of The Ion

The Ion Houston names 3 new execs to its team

new hires

The Ion, an entrepreneurship center being developed in the old Sears building in Midtown by the Rice Management Company, has named three new senior directors to its team.

Deanea LeFlore, Jan E. Odegard, and Chris Valka are the three newly named leaders of the organization, effective immediately. They join — and will report to — Gabriella Rowe, who was named executive director in October.

"To grow the Houston innovation system and spearhead our mission for the Ion we've hired three new leaders with fresh perspectives, ideas, and approaches," says Allison K. Thacker, president and chief investment officer of the Rice Management Company, in a news release. "Each individual has a unique connection to Houston and the Ion, and we're thrilled to have them join our effort to build on the culture of innovation across our city, and within the community we're cultivating at the Ion."

To focus on the Ion's Academic Partner Network, Jan E. Odegard has been appointed senior director of industry and academic partners. Odegard's background includes research and leadership at Rice University in computing. Odegard will also oversee The Ion's labs, which include human/robotics interaction lab, an immersive reality lab and an industrial prototyping lab.

Deanea LeFlore has been named senior director of community and corporate engagement. Like Rowe, LeFlore had a similar role at Station Houston before this new position. Before that, she spent most of her career working for the city of Houston and served under four Mayors over 17 years.

Lastly, Chris Valka, has been hired as senior director of operations, overseeing finance, accounting, human resources, operations, and facilities management. Prior to this position, Valka served in the president's cabinet overseeing a similar spectrum of responsibilities at the University of St. Thomas.

"As we prepare for The Ion's opening in early 2021, we are excited to welcome Deanea LeFlore, Dr. Jan E. Odegard, and Chris Valka, to our growing team," says Rowe in the release. "I am excited to see what this diverse group of experts will bring to our efforts to build an inclusive innovation hub in a tech-forward environment that promotes all that is great about Houston."

The 270,000-square-foot Ion building broke ground in July of last year and is slated to open in 2021. Recently, the organization announced its first programming partner — Rice University's Glasscock School of Continuing Studies, and select courses have already begun.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”